Home / People / Nick Beckett
Picture of Nick Beckett

Nick Beckett

Managing Partner
Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Co-Head of the CMS Life Sciences & Healthcare Group

CMS China
Beijing Representative Office
Room 1909, China Youth Plaza No. 19 Dongsanhuan North Road
Chaoyang District, Beijing 100026
China
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English, French
Dispute Resolution

Nick Beckett is Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick Beckett is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in Chambers & Partners, Legal 500, the PLC Lifesciences Handbook, Super Lawyers London, Who’s Who Legal Trademarks and Life Sciences (Patent Litigation and Transactional) and also Who’s Who Legal ‘Thought Leader for Life Sciences 2018’, Who’s Who Legal: Thought Leaders – Global Elite 2019 for Life Sciences and the Guide to the World’s Leading Trade Mark Law Practitioners.

Various

Relevant experience

  • One of the world’s leading information technology services companies and successfully defending it in China against a top Chinese state-owned enterprise and its subsidiaries in respect of a management consultancy project and an ERP project that our client implemented for them under a global strategic framework agreement.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions, including China.
  • A leading global bed specialist on the highly sensitive and important employment termination of its former management team in China, including its Managing Director and two senior sales leaders based on unsatisfactory performance and serious wrongdoings.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • Asahi Medical in patent litigation in the UK Patents Court and Court of Appeal for a large Japanese medical device company in connection with their blood filtration technology. This also entailed coordinating concurrent litigation across Europe and liaising with the client's Japanese and European patent attorneys.
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • Takeda on successfully opposing the grant of a competitor’s (Bethesda Pharmaceuticals Inc) European patent at the Opposition Division of the European Patent Office.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
  • Sports World International in numerous trade mark litigation matters relating to its own and licensed brands including Kangol, Diadora, Puma and Lonsdale.
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less

Memberships

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less
Intellectual Property

Nick Beckett is Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region.  Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in Chambers & Partners, Legal 500, the PLC Lifesciences Handbook, Super Lawyers London, Who’s Who Legal Trademarks and Life Sciences (Patent Litigation and Transactional) and also Who’s Who Legal ‘Thought Leader for Life Sciences 2018’, Who’s Who Legal: Thought Leaders – Global Elite 2019 for Life Sciences and the Guide to the World’s Leading Trade Mark Law Practitioners.

Various

Relevant experience

  • A European automotive manufacturer in its IP licensing and actions to protect its portfolio from alleged infringement in many jurisdictions by several companies, including China.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A world leading IT network company on the coordination of enforcement activity against a Chinese trademark infringer.
  • A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anti-counterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices and bringing together a network to service the client's needs.
  • An art tools manufacturer on the strategic restructuring of its trademark portfolio in China and the implementation of further agreements to bolster the value of its rights.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions. This involved coordinating patent litigation and patent prosecution, as well as advising the client on general commercial strategy.
  • A Hong Kong based biotechnology company on a freedom to operate (FTO) search on a number of its core products across Asia-Pacific.
  • BudejovickyMetanskyPivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER.
  • A major US pharmaceutical company in disputes with numerous parallel traders.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less

Memberships

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less
Life Sciences & Healthcare

Nick Beckett is Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP  and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in Chambers & Partners, Legal 500, the PLC Lifesciences Handbook, Super Lawyers London, Who’s Who Legal Trademarks and Life Sciences (Patent Litigation and Transactional) and also Who’s Who Legal ‘Thought Leader for Life Sciences 2018’, Who’s Who Legal: Thought Leaders – Global Elite 2019 for Life Sciences and the Guide to the World’s Leading Trade Mark Law Practitioners.

Various

Relevant experience

  • Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • A global pharmaceutical company on its market entry into China including obtaining relevant licence and setting up a compliance program, establishing its branch company in China and preparing and submitting the legal documents for the registration with the local authorities.
  • A world leading gas supplier on its joint medical institution project in China in cooperation with its domestic partner from various perspectives (corporate, compliance, regulatory and commercial).
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • One of the leading traditional Chinese medicine (TCM) companies in China in its management control dispute relating to a joint venture in The Netherlands.
  • Eli Lilly in a leading pharmaceutical parallel trade repackaging case before the CJEU.
  • A global leading medical device company on a strategically important investigation into a compliance breach within their distribution channels in Indonesia and South-East Asia.
  • A Japanese pharmaceutical company on conducting IP due diligence in respect of 2 anti-depressant compounds the subject of a successful world-wide collaboration agreement.
  • A Tianjin-based biotechnology company specialising in novel HIV biologics on international pre-clinical through to Phase III clinical trial development.  Identifying opportunities and facilitating introductions to potential R&D partners in Europe and North America.  Advising on potential entry into Western pharmaceutical markets and the feasibility of deal structures, including the licensing of intellectual property and establishing joint ventures.
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less

Memberships

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less

Feed

Show only
February 2019
Top de­vel­op­ments and pre­dic­tions for Anti-Trust in...
2018-2019
03 Dec 19
China Life Sci­ences & Health­care Up­date – Au­tumn 2019
SAMR so­li­cits com­ments on bio­lo­gic lot re­lease man­age­ment, 18 Novem­ber 2019 The State Ad­min­is­tra­tion for Mar­ket Reg­u­la­tion ("SAMR") of the People's Re­pub­lic of China ("PRC") re­leased the Cir­cu­lar on Seek­ing...
February 2019
Top de­vel­op­ments and pre­dic­tions for the Life Sci­ences...
2018-2019
26 Nov 19
China Monthly TMT Up­date - Novem­ber 2019
China passes Cryp­to­graphy Law The PRC Cryp­to­graphy Law has been passed and ad­op­ted. It will take ef­fect from 1 Janu­ary 2020. Un­der the Cryp­to­graphy Law, cryp­to­graphy refers to tech­no­lo­gies, products,...
February 2019
Top de­vel­op­ments and pre­dic­tions for the TMT Sec­tor...
2018-2019
08 Oct 19
China Monthly TMT Up­date – Oc­to­ber 2019
China is­sues opin­ions to reg­u­late edu­ca­tion­al ap­plic­a­tion pro­grams The Min­istry of Edu­ca­tion, the Cy­ber­se­cur­ity Ad­min­is­tra­tion of China, the Min­istry of In­dustry and In­form­a­tion Tech­no­logy and five oth­er...
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
19 Sep 19
China ex­pands cent­ral­ised drug pro­cure­ment scheme na­tion­wide
Fur­ther to the im­ple­ment­a­tion of its cent­ral­ised pro­cure­ment re­gime in 11 ma­jor cit­ies in Novem­ber 2018, China re­cently ex­pan­ded this re­gime to 29 provinces and four mu­ni­cip­al­it­ies across the coun­try...
28 Nov 18
Sup­port­ing you with data pro­tec­tion and cy­ber­se­cur­ity
CMS cap­ab­il­it­ies
04 Sep 19
China Monthly TMT Up­date - Septem­ber 2019
The Cy­ber­space Ad­min­is­tra­tion of China is­sues the Draft Ad­min­is­trat­ive Meas­ures for Cred­it In­form­a­tion on Ser­i­ously Dis­hon­est Sub­jects Of­fer­ing In­ter­net In­form­a­tion Ser­vices The Cy­ber­space Ad­min­is­tra­tion...
June 2018
CMS Guide to Anti-Bribery and Cor­rup­tion Laws
29 Aug 19
China an­nounces ma­jor changes to its drug reg­u­lat­ory re­gime
Fol­low­ing years of dis­cus­sion and de­bate, the 12th Ses­sion of the Stand­ing Com­mit­tee of Chin­a's Na­tion­al People's Con­gress passed the Amend­ment of the Drug Ad­min­is­tra­tion Law of the People’s Re­pub­lic...